Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.
about
A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphomaTumor infiltrating lymphocytes in ovarian cancerCost-effectiveness of treatment strategies for BRAF-mutated metastatic melanomaNovel immune checkpoint blocker approved for the treatment of advanced melanomaCharacterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.IL-27 induces the expression of IDO and PD-L1 in human cancer cells.Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.Targeted therapies for cutaneous T-cell lymphomas.Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft.Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients.CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.Crisis or self-correction: Rethinking media narratives about the well-being of science.
P2860
Q26780141-6D089B48-26B9-4F12-91B4-5EDE0A1FC9A2Q27021878-1694672F-24F8-4A17-9A58-432DE80B8B04Q28542877-D1F59CFD-7819-4C5F-B59D-7399E04EA4B8Q34936394-574D2E00-EDDA-46A0-9438-B47BF211CD6FQ35507112-10515BDB-045D-4BFA-B411-8CD784FC23CEQ35886444-2FEA0660-5FF8-48A1-92E6-40509FC70C6BQ36019013-3D11863E-0ED6-4721-B49D-CA2DB2DF8925Q36685395-ACB127D4-FB4D-42C2-A4F3-9D7F218C6696Q37323344-EA7DEA08-ECC0-4D17-AD5B-585A7842C065Q38229634-EB83C3BF-FD50-4464-B7E4-AD47734E6D32Q38910173-5D04442A-6008-4A52-B0A0-D049C859AF2DQ42391294-096D65E6-DDC0-4C88-922C-69CDAE36FA70Q47346032-3097ACD7-E068-415F-959F-30D55920A1E4Q47847652-B3B87BB1-67DF-47F4-AF64-1CAFA5D316CCQ48351257-50CB4F8B-BADF-47B1-86D1-1AA2E51162BFQ54981008-AD2D4041-3685-4ECC-B7B5-A570469053AEQ55262180-76C16A9A-B0C5-4941-819B-21F0FC8F4F91
P2860
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Harnessing the immune system t ...... lanoma and other solid tumors.
@en
Harnessing the immune system t ...... lanoma and other solid tumors.
@nl
type
label
Harnessing the immune system t ...... lanoma and other solid tumors.
@en
Harnessing the immune system t ...... lanoma and other solid tumors.
@nl
prefLabel
Harnessing the immune system t ...... lanoma and other solid tumors.
@en
Harnessing the immune system t ...... lanoma and other solid tumors.
@nl
P2860
P50
P356
P1433
P1476
Harnessing the immune system t ...... lanoma and other solid tumors.
@en
P2093
Alexander Eggermont
Jean Charles Soria
P2860
P304
P356
10.4161/ONCI.27560
P577
2014-01-03T00:00:00Z